Clinical Trial Update: Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant or adjuvant therapy with bevacizumab, epirubicin, cyclophosphamide, followed by docetaxel, trastuzumab, and bevacizumab in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-09-26